ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

Informasi Utama

  • Nama dagang:
  • ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT
  • Digunakan untuk:
  • manusia
  • Jenis Obat:
  • Perangkat medis

Dokumen

  • untuk masyarakat umum:
  • Informasi leaflet untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan untuk layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami mampu mendapatkannya.


    Meminta selebaran informasi untuk masyarakat umum.

Lokalisasi

  • Tersedia di:
  • ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT
    Indonesia
  • Bahasa:
  • Bahasa Indonesia

Informasi lainnya

Status

  • Sumber:
  • Ecolab
  • Nomor Otorisasi:
  • 913510
  • Pembaharuan Terakhir:
  • 12-03-2018

Ringkasan karakteristik Produk: dosis, interaksi, efek samping

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

1 / 10

BAGIAN 1. IDENTIFIKASI PRODUK DAN PERUSAHAAN

Nama produk

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

Cara identifikasi lainnya

Tidak berlaku.

Penggunaan yang dianjurkan

Pembersih

Pembatasan penggunaan

Disediakan untuk penggunaan industrial dan profesional.

Informasi pengenceran

produk

0.58 % - 0.78 %

Perusahaan

PT. Ecolab International Indonesia

Jl. Jababeka XII.B Kav V-37

Kawasan Industri Jababeka, Cikarang Indonesia 17530

(62-21) 8983 4891

Nomor telepon darurat

+1-651-222-5352 (Amerika Syarikat)

Tanggal penerbitan pertama

25.11.2016

BAGIAN 2. IDENTIFIKASI BAHAYA

Klasifikasi GHS

Produk TERJUAL

Toksisitas akut (Kulit)

Kategori 4

Iritasi mata

Kategori 2A

Sensitisasi kulit

Kategori 1

Penggunaan produk dicairkan

Bukan merupakan zat atau campuran yang berbahaya.

Elemen label GHS

Produk TERJUAL

Piktogram bahaya

Kata sinyal

Awas

Pernyataan Berbahaya

Berbahaya jika terkena kulit.

Dapat menyebabkan reaksi alergi pada kulit.

Menyebabkan iritasi mata yang serius.

Pernyataan Hati-hati

Pencegahan:

Hindari menghirup debu/asap/gas/kabut/uap/semburan. Cuci kulit

dengan seksama setelah menangani. Pakaian kerja yang

terkontaminasi tidak boleh dibawa keluar dari tempat kerja. Pakai

perlindungan mata/ perlindungan muka. Kenakan sarung tangan

pelindung/ pakaian pelindung.

Respons:

JIKA TERKENA KULIT: Cucilah dengan air yang banyak. JIKA

TERKENA MATA : Bilas dengan seksama dengan air untuk beberapa

menit. Lepaskan lensa kontak jika memakainya dan mudah

melakukannya.Lanjutkan membilas. Hubungi SENTRA INFORMASI

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

2 / 10

KERACUNAN atau dokter/enaga medis jika kamu merasa tidak sehat.

Jika terjadi iritasi pada kulit atau muncul ruam: Cari pertolongan

medis. Jika iritasi mata tidak segera sembuh: Cari pertolongan medis.

Tanggalkan pakaian yang terkominasi dan cuci sebelum dipakai

kembali.

Pembuangan:

Buang isi / wadah ke tempat pembuangan limbah yang disetujui.

Penggunaan produk dicairkan

Pernyataan Hati-hati

Pencegahan:

Cucilah tangan bersih-bersih setelah menangani.

Respons:

Dapatkan nasehat/perhatian medis jika kamu merasa tidak sehat.

Penyimpanan:

Simpan sesuai dengan peraturan setempat.

Produk TERJUAL

Bahaya lain

Jangan dicampur dengan pemutih atau produk lain yang mengandung

klor - akan menyebabkan gas klorin.

BAGIAN 3. KOMPOSISI/INFORMASI TENTANG BAHAN PENYUSUN

Produk TERJUAL

Bahan/preparasi murni

Campuran

Nama kimia

No-CAS

Konsentrasi (%)

L-(+)-lactic acid

79-33-4

10 - 30

Natrium Bisulfat

7681-38-1

5 - 10

Propylene glycol

57-55-6

1 - 5

NATRIUM DODESILBENZENASULFONAT

25155-30-0

1 - 5

Penggunaan produk dicairkan

Tidak ada zat berbahaya

BAGIAN 4. TINDAKAN PERTOLONGAN PERTAMA PADA KECELAKAAN

Produk TERJUAL

Jika kontak dengan mata

Basuhlah segera dengan banyak air, dan berikan air sebanyak-

banyaknya di bawah kelopak mata, sekurangnya selama 15 menit.

Lepas lensa kontak, jika digunakan dan mudah melakukannya.

Lanjutkan membilas. Cari dan dapatkan bantuan medis.

Jika kontak dengan kulit

Segera cuci bersih dengan banyak air sedikitnya selama 15 menit.

Gunakan sabun lunak bila tersedia. Cuci pakaian yang tercemar

sebelum dipakai lagi. Cucilah sebersih mungkin sepatu sebelum

dipakai lagi. Cari dan dapatkan bantuan medis.

Jika tertelan

Bilas mulut. Tangani secara medis jika muncul gejala.

Jika terhirup

Pindahkan ke tempat berudara segar. Tangani menurut gejala. Cari

dan dapatkan bantuan medis.

Perlindungan aiders pertama

Bila ada bahaya kontaminasi lihat bab 8 tentang perlengkapan

melindungi diri.

Instruksi kepada dokter

Tangani menurut gejala.

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

3 / 10

Gejala dan efek yang paling

penting, baik yang akut

maupun yang tertunda

Lihat bagian 11 untuk informasi yang lebih terperinci mengenai

berbagai efek dan gejala pada kesehatan.

Penggunaan produk dicairkan

Jika kontak dengan mata

Bilas dengan banyak air.

Jika kontak dengan kulit

Bilas dengan banyak air.

Jika tertelan

Bilas mulut. Tangani secara medis jika muncul gejala.

Jika terhirup

Tangani secara medis jika muncul gejala.

BAGIAN 5. TINDAKAN PEMADAMAN KEBAKARAN

Produk TERJUAL

Media pemadam yang sesuai

Gunakan tindakan pemadaman kebakaran yang sesuai untuk situasi

lokal dan lingkungan sekitar.

Zat pemadam kebakaran

yang tidak sesuai

Tidak ada yang diketahui.

Bahaya spesifik yang

diakibatkan bahan kimia

tersebut

Tidak mudah-menyala atau terbakar.

Produk pembakaran

berbahaya

Hasil penguraian mungkin termasuk bahan-bahan berikut:

Karbon oksida

Sulfur oksida

Alat pelindung khusus bagi

petugas pemadam

kebakaran

Gunakan alat pelindung diri.

Metode pemadaman khusus

Residu kebakaran dan air bekas pemadam kebakaran yang tercemar

harus dibuang sesuai dengan peraturan lokal. Jika terjadi kebakaran

dan/atau ledakan, jangan menghirup asap.

BAGIAN 6. TINDAKAN PENANGGULANGAN JIKA TERJADI TUMPAHAN DAN KEBOCORAN

Produk TERJUAL

Tindakan pencegahan

pribadi, peralatan pelindung

dan prosedur darurat

Pastikan agar pembersihan dilakukan hanya oleh petugas terlatih.

Mengaculah pada langkah-langkah perlindungan yang dicantumkan

dalam seksi 7 dan 8.

Tindakan pencegahan untuk

melindungi lingkungan

Jangan sampai mengenai tanah, air permukaan atau air tanah.

Metode dan bahan untuk

penyimpanan dan

pembersihan

Hentikan kebocoran jika aman untuk melakukannya. Tahan dan

kumpulkan tumpahan dengan bahan penyerap yang tidak mudah

terbakar (misalnya pasir, tanah, tanah diatomaceus, vermiculite) dan

tempatkan dalam kontener untuk dibuang berdasarkan peraturan

lokal/nasional (lihat seksi 13).Siramlah sisa-sisa dengan air. Untuk

tumpahan dalam jumlah banyak, bendung tumpahan bahan atau

tumpahan yang mengandung bahan materi untuk memastikan agar

tidak mengalir menuju saluran air.

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

4 / 10

Penggunaan produk dicairkan

Tindakan pencegahan

pribadi, peralatan pelindung

dan prosedur darurat

Mengaculah pada langkah-langkah perlindungan yang dicantumkan

dalam seksi 7 dan 8.

Tindakan pencegahan untuk

melindungi lingkungan

Tidak diperlukan tindakan pencegahan khusus untuk melindungi

lingkungan.

Metode dan bahan untuk

penyimpanan dan

pembersihan

Hentikan kebocoran jika aman untuk melakukannya. Tahan dan

kumpulkan tumpahan dengan bahan penyerap yang tidak mudah

terbakar (misalnya pasir, tanah, tanah diatomaceus, vermiculite) dan

tempatkan dalam kontener untuk dibuang berdasarkan peraturan

lokal/nasional (lihat seksi 13).Siramlah sisa-sisa dengan air. Untuk

tumpahan dalam jumlah banyak, bendung tumpahan bahan atau

tumpahan yang mengandung bahan materi untuk memastikan agar

tidak mengalir menuju saluran air.

BAGIAN 7. PENANGANAN DAN PENYIMPANAN

Produk TERJUAL

saran penanganan yang

aman

Jangan dimakan. Jangan sampai kena kulit dan mata. Jangan

menghirup debu/ asap/ gas/ kabut/ uap/ semburan. Gunakan hanya

dengan ventilasi yang cukup. Cucilah tangan bersih-bersih setelah

menangani. Jangan terkena mata, kulit atau pakaian. Jangan

dicampur dengan pemutih atau produk lain yang mengandung klor -

akan menyebabkan gas klorin.

Kondisi untuk penyimpanan

yang aman

Jauhkan dari zat-zat basa kuat. Jauhkan dari jangkauan anak-anak.

Jaga wadah tertutup rapat. Simpan dalam wadah yang berlabel

sesuai.

Suhu penyimpanan

0 °C ke 50 °C

Penggunaan produk dicairkan

saran penanganan yang

aman

Cucilah tangan setelah menangani. Untuk perlindungan pribadi lihat

seksi 8.

Kondisi untuk penyimpanan

yang aman

Jauhkan dari jangkauan anak-anak. Jaga wadah tertutup rapat.

Simpan dalam wadah yang berlabel sesuai.

BAGIAN 8. KONTROL PAPARAN/ PERLINDUNGAN DIRI

Produk TERJUAL

Komponen dengan parameter pengendalian di tempat kerja

Tidak mengandung bahan-bahan yang mempunyai nilai batas eksposur pekerjaan.

Pengendalian teknik yang

sesuai

Sistem ventilasi pembuangan yang efektif. Jaga konsentrasi udara di

bawah standar paparan okupasional.

Alat Pelindung Diri

Perlindungan mata

Kacamata-pengaman berpelindung-samping

Perlindungan tangan

Kenakan perlengkapan perlindungan pribadi berikut ini:

Jenis sarung tangan standar.

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

5 / 10

Sarung tangan harus dibuang atau diganti apabila terdapat indikasi

mengalami degradasi atau kebocoran kimia.

Perlindungan kulit

Tidak diperlukan peralatan perlindungan khusus.

Perlindungan pernapasan

Jika karyawan menghadapi konsentrasi yang melebihi ambang batas

pajanan, mereka harus memakai alat bantu pernapasan yang

memenuhi standar.

Tindakan higienis

Tangani sesuai dengan praktik kebersihan dan keselamatan industri

yang baik. Lepaskan dan cuci pakaian yang tercemar sebelum dipakai

lagi. Cuci muka, tangan dan kulit yang terpapar dengan seksama

setelah menangani.

Penggunaan produk dicairkan

Pengendalian teknik yang

sesuai

Ventilasi umum yang baik semestinya cukup untuk mengendalikan

pemaparan pekerja terhadap kadar kontaminasi yang terbawa-udara.

Alat Pelindung Diri

Perlindungan mata

Tidak diperlukan peralatan perlindungan khusus.

Perlindungan tangan

Tidak diperlukan peralatan perlindungan khusus.

Perlindungan kulit

Tidak diperlukan peralatan perlindungan khusus.

Perlindungan pernapasan

Biasanya tidak diperlukan alat bantu pelindung pernapasan pribadi.

BAGIAN 9. SIFAT FISIKA DAN KIMIA

Produk TERJUAL

Penggunaan produk dicairkan

Tampilan

: cair

cair

Warna

: buram, hijau tua

hijau muda

: Tak berbau

Tak berbau

0.5 - 1.0, 100 %

2.1 - 3.2

Titik nyala

cawan tertutupTidak berlaku.

Ambang Bau

Data tidak tersedia

Titik lebur/titik beku

Data tidak tersedia

Titik didih awal/rentang didih

> 100 °C

Laju penguapan

Data tidak tersedia

Flamabilitas (padatan, gas)

Data tidak tersedia

Tertinggi batas ledakan

Data tidak tersedia

Terendah batas ledakan

Data tidak tersedia

Tekanan uap

Data tidak tersedia

Kerapatan (densitas) uap

relatif

Data tidak tersedia

Berat jenis relatif

1.069 - 1.135

Kelarutan dalam air

larut

Kelarutan dalam pelarut lain

Data tidak tersedia

Koefisien partisi (n-

Data tidak tersedia

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

6 / 10

oktanol/air)

Suhu dapat membakar

sendiri (auto-ignition

temperature)

Data tidak tersedia

Dekomposisi termal

Data tidak tersedia

Viskositas, kinematis

907.757 mm2/s (40 °C)

Sifat peledak

Data tidak tersedia

Sifat oksidator

Bahan atau campuran ini tidak diklasifikasikan sebagai pengoksidasi.

Berat Molekul

Data tidak tersedia

Data tidak tersedia

BAGIAN 10. STABILITAS DAN REAKTIFITAS

Produk TERJUAL

Stabilitas kimia

Stabil pada kondisi normal.

Kemungkinan reaksi

berbahaya

Jangan dicampur dengan pemutih atau produk lain yang mengandung

klor - akan menyebabkan gas klorin.

Kondisi yang harus dihindari

Tidak ada yang diketahui.

Bahan non-kompatibel

Basa

Logam

Produk berbahaya hasil

peruraian

Hasil penguraian mungkin termasuk bahan-bahan berikut:

Karbon oksida

Sulfur oksida

BAGIAN 11. INFORMASI TOKSIKOLOGI

Informasi tentang rute

paparan

Penghirupan, Kena mata, Kena kulit

Kemungkinan Dampak Kesehatan

Produk TERJUAL

Mata

Menyebabkan iritasi mata yang serius.

Kulit

Berbahaya jika terkena kulit. Dapat menyebabkan reaksi alergi pada

kulit.

Tertelan

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Penghirupan

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Eksposur Kronis

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Penggunaan produk dicairkan

Mata

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

7 / 10

Kulit

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Tertelan

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Penghirupan

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Eksposur Kronis

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Pengalaman dengan paparan pada manusia

Produk TERJUAL

Kena mata

Kemerahan, Nyeri, Iritasi

Kena kulit

Kemerahan, Nyeri, Reaksi alergi

Tertelan

Tidak ada gejala yang diketahui atau diperkirakan.

Penghirupan

Tidak ada gejala yang diketahui atau diperkirakan.

Penggunaan produk dicairkan

Kena mata

Tidak ada gejala yang diketahui atau diperkirakan.

Kena kulit

Tidak ada gejala yang diketahui atau diperkirakan.

Tertelan

Tidak ada gejala yang diketahui atau diperkirakan.

Penghirupan

Tidak ada gejala yang diketahui atau diperkirakan.

Toksisitas

Produk TERJUAL

Produk

Toksisitas oral akut

: Oral LD50 : > 5,000 mg/kg

Bahan tes: Produk

Toksisitas inhalasi akut

: 4 h LC50 : > 2.0 mg/l

Bahan tes: Produk

Toksisitas kulit akut

: Data tidak tersedia

Kerusakan/gangguan kulit

: Tidak menyebabkan iritasi kulit

Bahan tes:Produk

Gangguan mata/kerusakan

mata serius

: Iritasi mata

Bahan tes: Produk

Sensitisasi sistem

pernafasan atau kulit

: Tidak menyebabkan sensitisasi kulit.

Bahan tes: Produk

Karsinogenisitas

Data tidak tersedia

Pengaruh pada alat

reproduksi

Data tidak tersedia

Mutagenitas sel germinal

Data tidak tersedia

Teratogenisitas

Data tidak tersedia

STOT - paparan tunggal

Data tidak tersedia

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

8 / 10

STOT - paparan berulang

Data tidak tersedia

Derajat keracunan melalui

pernapasan

Data tidak tersedia

Komponen

Toksisitas kulit akut

: L-(+)-lactic acid

LD50 Kelinci: > 2,000 mg/kg

BAGIAN 12. INFORMASI EKOLOGI

Produk TERJUAL

Derajat racun bagi lingkungan (ekotoksisitas)

Dampak lingkungan

Produk ini tidak mempunyai dampak racun lingkungan yang diketahui.

Produk

Keracunan untuk ikan

: Data tidak tersedia

Derajat racun bagi daphnia

dan binatang tak bertulang

belakang lainnya yang hidup

dalam air.

: Data tidak tersedia

Keracunan untuk ganggang

: Data tidak tersedia

Komponen

Keracunan untuk ikan

: L-(+)-lactic acid

96 h LC50 Ikan: 130 mg/l

Natrium Bisulfat

96 h LC50 Ikan: 7,960 mg/l

Propylene glycol

96 h LC50: > 10,000 mg/l

NATRIUM DODESILBENZENASULFONAT

96 h LC50: 3.2 mg/l

Komponen

Derajat racun bagi daphnia

dan binatang tak bertulang

belakang lainnya yang hidup

dalam air.

: Propylene glycol

48 h EC50: 18,340 mg/l

Komponen

Keracunan untuk ganggang

: Propylene glycol

96 h EC50: 19,000 mg/l

Ketahanan dan tingkat penguraian

Produk TERJUAL

Mudah terurai secara hayati.

Penggunaan produk dicairkan

Mudah terurai secara hayati.

Potensi penumpukan biologis

Data tidak tersedia

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

9 / 10

Mobilitas di dalam tanah

Data tidak tersedia

Dampak merugikan lainnya

Data tidak tersedia

BAGIAN 13. PERTIMBANGAN PEMBUANGAN/ PEMUSNAHAN

Produk TERJUAL

Metode pembuangan

Jika mungkin, pendauran-ulang lebih disukai daripada pembuangan

atau pembakaran. Jika proses daur-ulang tidak praktis, buang sesuai

dengan peraturan lokal. Buanglah sampah dalam fasilitas

pembuangan sampah yang disetujui.

Pembuangan limbah

Buang sebagai produk yang tidak digunakan. Wadah kosong harus

dibawa ke tempat penanganan limbah yang telah disetujui untuk

didaur-ulang atau dibuang. Dilarang menggunakan kembali

kemasan/wadah yang sudah kosong. Buanglah sesuai dengan

peraturan lokal, negara bagian, dan federal.

Penggunaan produk dicairkan

Metode pembuangan

Produk diencerkan dapat disalurkan ke saluran pembuangan sanitasi

Pembuangan limbah

Buanglah sesuai dengan peraturan lokal, negara bagian, dan federal.

BAGIAN 14. INFORMASI PENGANGKUTAN

Produk TERJUAL

Pengangkut/ pengirim barang/ pengirim bertanggung jawab untuk memastikan kemasan, label, dan

penandaan yang sesuai dengan jenis transportasi yang digunakan.

Transpor jalan

Bukan barang berbahaya

Transpor laut (IMDG/IMO)

Bukan barang berbahaya

BAGIAN 15. INFORMASI YANG BERKAITAN DENGAN REGULASI

Regulasi domestik

Sistem Harmonisasi Global Klasifikasi dan Label Pada Bahan Kimia (87/M-IND/PER/9/2009)

Komponen-komponen produk ini dilaporkan dalam inventorisasi berikut:

Swiss. Senyawa yang baru diumumkan dan preparat yang baru dilaporkan :

belum ditentukan

Inventaris TSCA Amerika Serikat :

Pada Inventaris TSCA

Daftar Senyawa Domestik Kanada :

Seluruh komponen produk ini terdapat pada daftar DSL Kanada

Australia. Undang-undang (Pengkajian dan Pemberitahuan) Kimia Industri :

Sesuai dengan inventaris

LEMBARAN DATA KESELAMATAN BAHAN

ANTIMICROBIAL FRUIT & VEGETABLE TREATMENT

913510

10 / 10

Selandia Baru. Inventaris Bahan Kimia (NZIoC), seperti yang diterbitkan oleh ERMA Selandia

Baru :

Sesuai dengan inventaris

Jepang. ENCS - Inventaris Senyawa Kimia Yang Sudah Ada Dan Yang Baru :

belum ditentukan

Jepang. ISHL - Inventaris Senyawa Kimia (METI) :

belum ditentukan

Korea. Inventaris Bahan Kimia Yang Sudah Ada (KECI) :

Sesuai dengan inventaris

Inventaris Bahan Kimia dan Senyawa Kimia Filipina (PICCS) :

Sesuai dengan inventaris

Cina. Inventaris Senyawa Kimia yang Sudah Ada :

Sesuai dengan inventaris

BAGIAN 16. INFORMASI LAIN

Tanggal penerbitan pertama

25.11.2016

Versi

Disiapkan oleh

Urusan peraturan

Perbahan-perubahan peraturan atau informasi kesehatan yang signifikan dalam revisi ini ditunjukkan

oleh batang di bagian sisi kiri MSDS.

Informasi yang diberikan dalam Lembar Data Keselamatan ini benar menurut pengetahuan, informasi,

dan keyakinan kami pada tanggal penerbitan. Informasi yang diberikan dimaksudkan hanya sebagai

pedoman untuk penanganan, penggunaan, pemprosesan, penyimpanan, pengangkutan,

pembuangan, dan pembebasan yang aman dan tidak boleh dianggap sebagai jaminan atau

spesifikasi mutu. Informasi hanya menyangkut bahan spesifik yang telah ditentukan dan dapat tidak

berlaku jika bahan tersebut digunakan sebagai campuran dengan bahan lain atau dalam proses lain

kecuali jika dinyatakan secara spesifik dalam tulisan.

14-2-2019

FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices

FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices

FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices

FDA - U.S. Food and Drug Administration

8-2-2019


Draft guideline on clinical investigation of medicinal products for the treatment of gout

Draft guideline on clinical investigation of medicinal products for the treatment of gout

Draft guideline on clinical investigation of medicinal products for the treatment of gout

Europe - EMA - European Medicines Agency

6-2-2019

FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder

FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder

FDA approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening disorder that causes blood clotting.

FDA - U.S. Food and Drug Administration

5-2-2019


Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Categorisation of antimicrobials

Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Categorisation of antimicrobials

Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Categorisation of antimicrobials

Europe - EMA - European Medicines Agency

1-2-2019

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Published on: Thu, 31 Jan 2019 The EFSA FEEDAP Panel previously (2016) could not conclude on the safety of certain concentrated liquid l‐lysine (base), l‐lysine monohydrochloride (HCl) and l‐lysine sulfate products manufactured using different strains of Corynebacterium glutamicum. New information on the safety of these products was provided by the applicant. The recipient strain C. glutamicum KCTC 12307BP qualifies for qualified presumption of safety (QPS) approach for safety assessment, the genetic mo...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-2-2019

EFSA statement on the risk posed to humans by a vitamin B2 produced by a genetically modified strain of Bacillus subtilis used as a feed additive

EFSA statement on the risk posed to humans by a vitamin B2 produced by a genetically modified strain of Bacillus subtilis used as a feed additive

Published on: Thu, 31 Jan 2019 The detection of recombinant DNA in a vitamin B2 used as feed additive was notified by the Belgian national authorities on 2 October 2018 via the Rapid Alert System for Food and Feed (RASFF). The European Commission requested scientific advice from EFSA on the risk posed to humans by the presence of genetically modified material in the feed additive, particularly with regard to antimicrobial resistance (AMR). EFSA assessed the analytical data from RASFF regarding the prese...

Europe - EFSA - European Food Safety Authority EFSA Journal

31-1-2019

User manual for mapping Member State zoonoses standard terminology to EFSA standard terminology for information derived from the year 2018

User manual for mapping Member State zoonoses standard terminology to EFSA standard terminology for information derived from the year 2018

Published on: Wed, 30 Jan 2019 The European Food Safety Authority (EFSA) is tasked with coordinating the reporting of zoonoses, zoonotic agents, animal populations, antimicrobial resistance and food‐borne outbreaks in the European Union (EU) under Directive 2003/99/EC, as well as analysing and summarising the data collected. For data transmission purposes, EFSA created a simple Microsoft Office Excel‐based mapping tool to allow Member States to map their standard terminology to EFSA's standard terminolo...

Europe - EFSA - European Food Safety Authority EFSA Journal

31-1-2019

Manual for reporting on antimicrobial resistance within the framework of Directive 2003/99/EC and Decision 2013/652/EU for information derived from the year 2018

Manual for reporting on antimicrobial resistance within the framework of Directive 2003/99/EC and Decision 2013/652/EU for information derived from the year 2018

Published on: Wed, 30 Jan 2019 This manual provides guidance for reporting antimicrobial resistance under the framework of Directive 2003/99/EC and Commission Implementing Decision 2013/652/EU in food‐producing animals and foodstuffs derived thereof. The objective is to harmonise and streamline the reporting made by the Member States to ensure that the antimicrobial resistance data collected are relevant and easy to analyse at the European Union level. Detailed guidelines are provided for the reporting ...

Europe - EFSA - European Food Safety Authority EFSA Journal

31-1-2019

Data dictionaries‐guidelines for reporting 2018 data on zoonoses, antimicrobial resistance and food‐borne outbreaks

Data dictionaries‐guidelines for reporting 2018 data on zoonoses, antimicrobial resistance and food‐borne outbreaks

Published on: Wed, 30 Jan 2019 This technical report of the European Food Safety Authority (EFSA) presents guidance to reporting European Union (EU) Member States and non‐Member States in data submission using extensible markup language (XML) data transfer covering the reporting of isolate‐based quantitative antimicrobial resistance data, as well as reporting of prevalence data on zoonoses and food‐borne contaminants, food‐borne outbreak data, animal population data and disease status data. For data col...

Europe - EFSA - European Food Safety Authority EFSA Journal

30-1-2019

FDA approves first generic Advair Diskus

FDA approves first generic Advair Diskus

FDA approved the first generic of Advair Diskus for treatment of asthma and maintenance treatment of airflow obstruction and reducing exacerbations with COPD.

FDA - U.S. Food and Drug Administration

25-1-2019

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Published on: Thu, 24 Jan 2019 The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic pre‐evaluation to support safety risk assessments of biological agents performed by EFSA's Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit are, where possible and reasonable in number, reflected by ‘qualifications’ which should be assessed at the strain lev...

Europe - EFSA - European Food Safety Authority EFSA Journal

24-1-2019

Perrigo Issues Allergy Alert For Simple Truth Organic Banana, Strawberry & Apple Puree With Nonfat Greek Yogurt

Perrigo Issues Allergy Alert For Simple Truth Organic Banana, Strawberry & Apple Puree With Nonfat Greek Yogurt

Perrigo Company, in coordination with The Kroger Company, is initiating a voluntary recall of one production lot of Simple Truth Organic Banana, Strawberry & Apple Fruit Puree with Nonfat Greek Yogurt (LOT L8159, best by 08/06/2019, produced in Spain) due to improper labeling that does not indicate the presence of milk, posing a potential risk to consumers with milk allergies.

FDA - U.S. Food and Drug Administration

22-1-2019

Peer review of the pesticide risk assessment of the active substance fenamiphos

Peer review of the pesticide risk assessment of the active substance fenamiphos

Published on: Mon, 21 Jan 2019 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Greece and co‐rapporteur Member State Cyprus for the pesticide active substance fenamiphos are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of fenamiphos as a nematic...

Europe - EFSA - European Food Safety Authority EFSA Journal

19-1-2019

Modification of the existing maximum residue levels for spirotetramat in various crops

Modification of the existing maximum residue levels for spirotetramat in various crops

Published on: Fri, 18 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the competent national authority in Belgium prepared a request to modify the existing maximum residue levels (MRLs) for the active substance spirotetramat in Florence fennels and rhubarbs. Furthermore, in accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer SAS submitted a request to the competent national authority in Austria to modify the existing MRLs for spirotetramat in the group of ...

Europe - EFSA - European Food Safety Authority EFSA Journal

14-1-2019


Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Europe - EMA - European Medicines Agency

8-1-2019

Happy Together, Inc. Issues Voluntary Nationwide Recall of Product Due to Presence of Undeclared Sildenafil and Tadalafil

Happy Together, Inc. Issues Voluntary Nationwide Recall of Product Due to Presence of Undeclared Sildenafil and Tadalafil

Happy Together, Inc. Boynton Beach, FL is voluntarily recalling all lots within expiry of the Rhino 5k capsules to the consumer level. FDA analysis founds these products to be tainted with sildenafil and Tadalafil. Sildenafil/Tadalafil is an FDA approved drug for the treatment of erectile dysfunction, the presence of sildenafil in the Rhino 5k products renders them unapproved drugs for which safety and efficacy have not been established, therefor subject to recall.

FDA - U.S. Food and Drug Administration

8-1-2019

Monitoring sales of veterinary antimicrobials

Monitoring sales of veterinary antimicrobials

Veterinary antimicrobial sales have been monitored annually by the Agency since 1999. This monitoring is based on the recommendations in Chapter 6.8 of the OIE's 2016 Terrestrial Animal Health Code "Monitoring of the quantities and usage patterns of antimicrobial agents used in food-producing animals".

France - Agence Nationale du Médicament Vétérinaire

8-1-2019

Resapath

Resapath

The development of antimicrobial resistance in animal and human bacteria is a major public health issue requiring an integrated approach across all types of medicine, according to the "One Health" concept covering both humans and animals. ANSES has mobilised significant resources to combat antimicrobial resistance, in particular by coordinating the French Surveillance Network for Antimicrobial Resistance in Pathogenic Bacteria of Animal Origin (Resapath), which is devoted to monitoring resistance in bact...

France - Agence Nationale du Médicament Vétérinaire

8-1-2019

Antimicrobial resistance

Antimicrobial resistance

Antimicrobial resistance is a major international human and animal health issue, because the emergence and spread of drug-resistant strains of bacteria call into question the efficacy of these treatments in humans and animals alike. Preserving the effectiveness of antibiotics is therefore a genuine public health challenge requiring an integrated approach across all types of medicine, according to the "One Health" concept covering both humans and animals. ANSES has mobilised significant resources to addr...

France - Agence Nationale du Médicament Vétérinaire

24-12-2018

Columbia River Natural Pet Foods Inc. Voluntarily Expands Recall to Include Cow Pie and Chicken & Vegetables Fresh Frozen Meats for Dogs and Cats Due to Possible Health Risk

Columbia River Natural Pet Foods Inc. Voluntarily Expands Recall to Include Cow Pie and Chicken & Vegetables Fresh Frozen Meats for Dogs and Cats Due to Possible Health Risk

Columbia River Natural Pet Foods of Vancouver, WA is voluntarily expanding their current recall to include additional products: 261 packages of Cow Pie Lot # 72618 and 82 packages of Chicken & Vegetables Lot# 111518 fresh frozen meats for dogs and cats, produced in July 2018 and November 2018, due to their potential to be contaminated with Salmonella and Listeria monocytogenes

FDA - U.S. Food and Drug Administration

22-12-2018

Modification of the existing maximum residue level for captan in hops

Modification of the existing maximum residue level for captan in hops

Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant ADAMA Agriculture BV on behalf of ADAMA Makhteshim Ltd. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue level for the active substance captan in hops. The data submitted in support of the request were found to be insufficient to conclude whether the existing residue definitions are appropriate for hops. Although the number of residue ...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-12-2018

FDA approves new treatment for adult patients with rare, life-threatening blood disease

FDA approves new treatment for adult patients with rare, life-threatening blood disease

The FDA approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.

FDA - U.S. Food and Drug Administration

21-12-2018

FDA approves first treatment for rare blood disease

FDA approves first treatment for rare blood disease

The FDA approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.

FDA - U.S. Food and Drug Administration

21-12-2018

One lot of Equate brand Lens Care System and Multi-Purpose Solution voluntarily recalled because of a labelling error

One lot of Equate brand Lens Care System and Multi-Purpose Solution voluntarily recalled because of a labelling error

Teva Canada is voluntarily recalling one lot (Lot 150261) of two products because of a labelling error. While the outer carton of Equate brand Lens Care System is correctly labelled, the bottle within the carton is mislabelled as Equate brand Multi-Purpose Solution. Because of the labelling error, the company is recalling both products labelled with Lot 150261. Bottles labelled as Equate Multi-Purpose Solution should contain a 0.0001% w/v polyhexanide based disinfecting solution for rinsing. The mislabel...

Health Canada

15-2-2019

#ICYMI: FDA authorizes first interoperable insulin pump intended to  allow patients to customize treatment through their individual diabetes  management devices. Read more here:  https://go.usa.gov/xEUuM   #MedicalDevice #FDA

#ICYMI: FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices. Read more here: https://go.usa.gov/xEUuM  #MedicalDevice #FDA

#ICYMI: FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices. Read more here: https://go.usa.gov/xEUuM  #MedicalDevice #FDA

FDA - U.S. Food and Drug Administration

13-2-2019


Orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase, Treatment of ornithine transcarbamylase deficiency, 20/03/2017, Positive

Orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase, Treatment of ornithine transcarbamylase deficiency, 20/03/2017, Positive

Orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase, Treatment of ornithine transcarbamylase deficiency, 20/03/2017, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus, 12/12/2017, Positive

Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus, 12/12/2017, Positive

Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus, 12/12/2017, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Humanised single-chain monoclonal antibody against CD37 (otlertuzumab), Treatment chronic lymphocytic leukaemia, 06/12/2012, Positive

Orphan designation: Humanised single-chain monoclonal antibody against CD37 (otlertuzumab), Treatment chronic lymphocytic leukaemia, 06/12/2012, Positive

Orphan designation: Humanised single-chain monoclonal antibody against CD37 (otlertuzumab), Treatment chronic lymphocytic leukaemia, 06/12/2012, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Europe - EMA - European Medicines Agency

5-2-2019


Risk classification of antimicrobials used in animals opens for public consultation

Risk classification of antimicrobials used in animals opens for public consultation

Risk classification of antimicrobials used in animals opens for public consultation

Europe - EMA - European Medicines Agency

1-2-2019


First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

Europe - EMA - European Medicines Agency

28-1-2019


Orphan designation: Pegylated B-domain-deleted sequence-modified recombinant human factor VIII (damoctocog alfa pegol), Treatment of haemophilia A, 23/02/2011, Positive

Orphan designation: Pegylated B-domain-deleted sequence-modified recombinant human factor VIII (damoctocog alfa pegol), Treatment of haemophilia A, 23/02/2011, Positive

Orphan designation: Pegylated B-domain-deleted sequence-modified recombinant human factor VIII (damoctocog alfa pegol), Treatment of haemophilia A, 23/02/2011, Positive

Europe - EMA - European Medicines Agency

28-1-2019


Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Mannitolum, Treatment of cystic fibrosis, 07/11/2005, Positive

Orphan designation: Mannitolum, Treatment of cystic fibrosis, 07/11/2005, Positive

Orphan designation: Mannitolum, Treatment of cystic fibrosis, 07/11/2005, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem

Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem

Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem cell transplantation, 20/03/2017, Positive

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Orphan designation: Octreotide acetate (oral use), Treatment of acromegaly, 05/08/2013, Positive

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Europe - EMA - European Medicines Agency

23-1-2019


Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody, Treatment of neuromyelitis optica spectrum disorders, 27/06/2016, Positive

Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody, Treatment of neuromyelitis optica spectrum disorders, 27/06/2016, Positive

Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody, Treatment of neuromyelitis optica spectrum disorders, 27/06/2016, Positive

Europe - EMA - European Medicines Agency

23-1-2019


No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life

No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life

No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: Moxetumomab pasudotox, Treatment of B-lymphoblastic leukaemia / lymphoma, 17/07/2013, Positive

Orphan designation: Moxetumomab pasudotox, Treatment of B-lymphoblastic leukaemia / lymphoma, 17/07/2013, Positive

Orphan designation: Moxetumomab pasudotox, Treatment of B-lymphoblastic leukaemia / lymphoma, 17/07/2013, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: Chimeric monoclonal antibody against GD2, Treatment of neuroblastoma, 08/11/2012, Positive

Orphan designation: Chimeric monoclonal antibody against GD2, Treatment of neuroblastoma, 08/11/2012, Positive

Orphan designation: Chimeric monoclonal antibody against GD2, Treatment of neuroblastoma, 08/11/2012, Positive

Europe - EMA - European Medicines Agency

14-1-2019


Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobials

Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobials

Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobials

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of retinitis pigmentosa, 28/07/2015, Positive

Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of retinitis pigmentosa, 28/07/2015, Positive

Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of retinitis pigmentosa, 28/07/2015, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of leber's congenital amaurosis, 02/04/2012, Positive

Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of leber's congenital amaurosis, 02/04/2012, Positive

Orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec), Treatment of leber's congenital amaurosis, 02/04/2012, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Autologous skeletal myoblasts expanded ex vivo, Treatment of oculopharyngeal muscular dystrophy, 13/04/2018, Negative

Orphan designation: Autologous skeletal myoblasts expanded ex vivo, Treatment of oculopharyngeal muscular dystrophy, 13/04/2018, Negative

Orphan designation: Autologous skeletal myoblasts expanded ex vivo, Treatment of oculopharyngeal muscular dystrophy, 13/04/2018, Negative

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid, Treatment of dermatomyositis, , Positive

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid, Treatment of dermatomyositis, , Positive

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid, Treatment of dermatomyositis, , Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia

Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia

Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia A, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment of maple syrup urine disease, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

4-1-2019


Orphan designation: Glibenclamide for the treatment of neonatal diabetes, Treatment of neonatal diabetes, 15/01/2016, Positive

Orphan designation: Glibenclamide for the treatment of neonatal diabetes, Treatment of neonatal diabetes, 15/01/2016, Positive

Orphan designation: Glibenclamide for the treatment of neonatal diabetes, Treatment of neonatal diabetes, 15/01/2016, Positive

Europe - EMA - European Medicines Agency

4-1-2019


Orphan designation: avapritinib, Treatment of mastocytosis, 26/10/2018, Positive

Orphan designation: avapritinib, Treatment of mastocytosis, 26/10/2018, Positive

Orphan designation: avapritinib, Treatment of mastocytosis, 26/10/2018, Positive

Europe - EMA - European Medicines Agency